share_log

Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

Canaccord Genuity維持對Oramed Pharmicals的控制,將目標價下調
Benzinga ·  2023/05/17 10:08

Canaccord Genuity analyst Edward Nash maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Hold and lowers the price target from $3 to $2.

Canaccord Genuity分析師愛德華·納什維持Oramed Pharmicals(納斯達克股票代碼:ORMP)的持倉,並將目標股價從3美元下調至2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論